Dapagliflozin/metformin - AstraZeneca

Drug Profile

Dapagliflozin/metformin - AstraZeneca

Alternative Names: Dapagliflozin/metformin FDC; Metformin/dapagliflozin; Oxramet; Xigduo FDC; Xigduo XR; Xigduo XR FDC

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca
  • Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Glucosides; Pyrans; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 28 Nov 2017 AstraZeneca completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in United Kingdom (PO) (NCT03138356)
  • 28 Nov 2017 AstraZeneca terminates a phase I bioequivalence trial in healthy volunteers in Brazil, due to the need to re-design the study as subject drop-out rate during screening was too high (NCT03216278)
  • 26 Sep 2017 AstraZeneca initiates enrolment in a phase I bioequivalence trial in healthy volunteers in Brazil (NCT03216278)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top